MTDH targeted antisense oligonucleotide therapeutic - Secarna Pharmaceuticals/Firebrand Therapeutics
Alternative Names: AEG-1 targeted antisense oligonucleotide therapeutic - Secarna Pharmaceuticals/Firebrand Therapeutics; Metadherin targeted antisense oligonucleotide therapeutic - Secarna Pharmaceuticals/Firebrand TherapeuticsLatest Information Update: 02 Jan 2024
At a glance
- Originator Firebrand Therapeutics; Secarna Pharmaceuticals
- Developer Secarna Pharmaceuticals
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Gene silencing; MTDH protein expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer